Answers are grounded in this paper and cite their sources.
Natural killer (NK)-cells are innate immune cells with potent anti-tumor capacity, capable of recognizing target cells without prior exposure.For this reason, NK-cells are recognized as a useful source of cell therapy.Although most NK-cells are derived from the bone marrow (BM), a separate developmental pathway in the thymus also exists, producing so-called thymic NK-cells.Unlike conventional NK-cells, thymic NK (tNK)-cells have a combined capacity for cytokine production and a natural ability to kill tumor cells in the presence of NK-cell receptor stimulatory ligands.Furthermore, tNK-cells are reported to express CD3 subunits intracellularly, without the presence of a rearranged T-cell receptor (TCR).This unique feature may enable harnessing of these cells with a TCR to combine NK-and T-cell effector properties in one cell type.The development, phenotype, and function of tNK-cells, and potential as a cell therapy is, however, poorly explored.In this review, we provide an overview of current literature on both murine and human tNK-cells in comparison to conventional BM-derived NK-cells, and discuss the potential applications of this cellular subset in the context of cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Forbes et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: